Smith & Nephew (NYSE:SNN) was upgraded by equities research analysts at HSBC from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.
Other equities analysts also recently issued reports about the company. Canaccord Genuity restated a “buy” rating on shares of Smith & Nephew in a research note on Thursday, February 8th. Morgan Stanley downgraded Smith & Nephew from an “overweight” rating to an “equal weight” rating in a research note on Monday, December 11th. ValuEngine downgraded Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, February 9th. Zacks Investment Research upgraded Smith & Nephew from a “sell” rating to a “hold” rating in a research note on Wednesday, February 7th. Finally, JPMorgan Chase & Co. upgraded Smith & Nephew from a “neutral” rating to an “overweight” rating in a research note on Thursday, January 25th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $44.00.
Smith & Nephew (NYSE:SNN) opened at $37.01 on Monday. The company has a quick ratio of 1.06, a current ratio of 2.03 and a debt-to-equity ratio of 0.31. Smith & Nephew has a 52 week low of $30.73 and a 52 week high of $40.43.
About Smith & Nephew
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.